UBS Group Reiterates “Buy” Rating for Bayer (BAYN)
UBS Group reissued their buy rating on shares of Bayer (FRA:BAYN) in a research report report published on Monday, www.boersen-zeitung.de reports.
A number of other analysts have also recently commented on the stock. Barclays set a €100.00 ($119.05) target price on shares of Bayer and gave the company a sell rating in a report on Tuesday, December 12th. Commerzbank set a €124.00 ($147.62) target price on shares of Bayer and gave the company a buy rating in a report on Wednesday, November 15th. Nord/LB set a €102.00 ($121.43) price objective on shares of Bayer and gave the stock a neutral rating in a research note on Friday, December 8th. Berenberg Bank set a €124.00 ($147.62) price objective on shares of Bayer and gave the stock a neutral rating in a research note on Tuesday, December 5th. Finally, Baader Bank set a €140.00 ($166.67) price objective on shares of Bayer and gave the stock a buy rating in a research note on Thursday, December 14th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of €121.71 ($144.90).
Shares of Bayer (FRA BAYN) traded up €0.60 ($0.71) during mid-day trading on Monday, reaching €104.08 ($123.90). 2,842,251 shares of the company’s stock were exchanged. Bayer has a twelve month low of €100.60 ($119.76) and a twelve month high of €123.82 ($147.40). The stock has a market capitalization of $85,980.00 and a PE ratio of 27.90.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.